Brief: Carmell Sharpens Aesthetics Focus With Execution Of Definitive Agreement To Sell Axolotl Biologix Subsidiary
20/03/2024 20:46
March 21 (Reuters) - Carmell Corp CTCX.O :
* CARMELL SHARPENS AESTHETICS FOCUS WITH EXECUTION OF
DEFINITIVE
AGREEMENT TO SELL AXOLOTL BIOLOGIX SUBSIDIARY
* CARMELL CORP: PROPOSED DEAL FOR $8 MILLION
Source text for Eikon: ID:nGNX8825g4
Further company coverage: CTCX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Longevity Health Holdings
See all newsBrief: Longevity Health Holdings Closes Strategic Investment And Appoints Ram Ajjarapu As Chairman And CEO To Drive Acquisition-Focused Growth
Brief: Longevity Health Holdings Says Merger Agreement To Terminate On July 8, If Not Extended - SEC Filing
Brief: Longevity Health Extends Partnership With Humana Through 2030
Brief: Longevity Health Holdings Announces Reverse Stock Split
Brief: Longevity Health Holdings Announces Execution Of Merger Agreement With 20/20 Biolabs